Paxene Wins ODAC Backing for Use In AIDS-Associated Kaposi’s Sarcoma
October 1st 1997BETHESDA, Md-For the second time in as many meetings, the Oncologic Drugs Advisory Committee (ODAC) has recommended that the FDA approve a paclitaxel-based drug for the treatment of AIDS-related Kaposi’s sarcoma (KS).
University of Pittsburgh Apologizes to Dr. Bernard Fisher
October 1st 1997PITTSBURGH-Bernard Fisher, MD, Distinguished Service Professor at the University of Pittsburgh, has accepted an apology and cash settlement from the University of Pittsburgh, and withdrawn his defamation suit against the University and the federal government.
How Budget Affects Physicians Who See Medicare Patients
October 1st 1997The fiscal year (FY) 1998 Balanced Budget Act contains several important changes in the Medicare program that affect physicians, including a go-ahead for provider-sponsored organizations (PSOs) (closed networks run by hospitals, doctors, and other providers instead of insurance companies) and new opportunities for the private sector to compete in the Medicare+Choice plans.
Coincidence Detection Allows Wider Use of FDG Scans
October 1st 1997GLASGOW-Gamma camera molecular coincidence detection (MCD) technology allows imaging of positron-emitting radiotracers such as FDG without the need for a dedicated PET scanner, and thus should make FDG imaging much more widely available, Henry N. Wagner, Jr., MD, professor of radiation health sciences at Johns Hopkins Medical Institutions, told Oncology News International.
Treatment Practices for Early Laryngeal Cancer Tend to Vary
October 1st 1997SAN FRANCISCO-Treatment practices often vary in the United States between physicians and across geographic regions, and such variation may be more likely when definitive comparisons of treatment modalities are lacking, as is the case with the management of early laryngeal carcinoma.
Camp for Children With Cancer Has Its 15th Anniversary
October 1st 1997IDYLLWILD, Calif-Actor Dustin Hoffman joined “Ronald McDonald,” the McDonald’s restaurant clown, and nearly 100 campers and their families in celebrating the 15th anniversary of Camp Ronald McDonald for Good Times-one of the nation’s oldest and largest year-round recreational camping programs for children with cancer.
Foundation Sponsors National Lymphoma Awareness Week
October 1st 1997LOS ANGELES-The Lymphoma Research Foundation of America launched its second annual National Lymphoma Awareness Week on October 12. Actress Kelly Lynch, whose sister Robyn Lynch is a lymphoma survivor, served as honorary chair of the week, which featured a slate of events to inform the public about this cancer.
Center Sponsors Creative Workshops for Women With Cancer
October 1st 1997NEW YORK-A strong belief in the healing power of creative activity spurred Geraldine Herbert to establish a place where women with cancer could go to express themselves through the visual, performing, literary, and domestic arts-The Creative Center for Women With Cancer, located in New York City.
Kodak Oncology Imaging Film System Wins R&D 100 Award
October 1st 1997ROCHESTER, NY-The Eastman Kodak Company has been selected to receive the 1997 R&D 100 Award for its development of the Kodak EC-L film system for oncology imaging. The award-winning system provides high-contrast images for use in monitoring radiation treatment of cancer patients.
First US Trial of Green Tea in Cancer Patients Is Underway
October 1st 1997HOUSTON-The first clinical study in the United States of green tea as an anticancer agent is underway at The University of Texas M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. If this trial and future studies show a benefit, the next step would be to get Americans to switch from their usual “black” tea to the Asian green variety, which has a milder flavor.
PDT Appears Effective for Oral Cavity, Laryngeal Cancers
October 1st 1997SAN FRANCISCO-Photodynamic therapy (PDT), using light tuned to specific wavelengths in order to activate a previously administered photosensitizing drug, holds significant promise as a new treatment modality for malignancies of the oral cavity and larynx, said Vanessa Schweitzer, MD, clinical professor of otolaryngology at the University of Michigan and senior staff physician at Henry Ford Health Care Systems, Detroit. [See page 64 for more on new uses of PDT.]
CDC Records First Drop in Number of New AIDS Cases
October 1st 1997WASHINGTON-New cases of AIDS in the United States have fallen for the first time in the 16 years of the epidemic, dropping by 6% in 1996 from 1995 levels. The main reason for the fall, most experts believe, is the use of combination regimens including protease inhibitors that prevent HIV infection from progressing to AIDS. It is also possible that fewer individuals are becoming infected with the AIDS virus.
Gene Mutations May Slow Progression of HIV
October 1st 1997FREDERICK, Md-Mutations in two genes that produce chemokine receptors-CCR5 and CCR2-account for about 30% of long-term survivors of HIV infection, that is, patients whose disease has not progressed to AIDS within 10 to 20 years of infection, said Stephen J. O’ Brien, PhD, of the NCI’s Laboratory of Genomic Diversity.
Public Health Groups Close Ranks Against Tobacco Industry
October 1st 1997WASHINGTON-The Administration’s demand that Congress strengthen areas of the proposed tobacco agreement (see article above) won praise from a number of organizations that had criticized the initial settlement as too weak. “The opportunity to enact the right tobacco policy has never been greater,” said John R. Seffrin, PhD, chief executive officer of the American Cancer Society.
Lessons Shared on How to Improve Cancer Pain Management
October 1st 1997SAN DIEGO-Accepting an award for her national efforts to make cancer pain management a top priority, Betty R. Ferrell, PhD, RN, used her lecture opportunity to outline 10 philosophical precepts, or “lessons,” that form the basis for the development of good cancer pain management in the institutional setting.
FDA Plans to Get Tough On Clinical Trials That Don’t Include Women
October 1st 1997WASHINGTON-The FDA has proposed a new regulation that would make sure pharmaceutical companies comply with a 1993 order to include women in all phases of drug testing. An examination of some 4,000 trials done in the last three years showed that approximately one quarter still excluded women of childbearing age solely because they could become pregnant during the trial.
Gene Therapy Is Moving Toward Cancer Treatment
October 1st 1997SAN FRANCISCO-About 4,000 human diseases have a genetic cause, and many such diseases are untreatable or poorly treated by conventional medicine, said R. Michael Blaese, MD, chief of the Clinical Gene Therapy Branch at the NIH National Center for Human Genome Research. In theory, many of these diseases could be treated by adding, deleting, or altering genes.
Is Axillary Dissection Always Indicated in Invasive Breast Cancer?
October 1st 1997The authors provide a comprehensive overview of the role of axillary lymphadenectomy in the treatment of early-stage breast cancer. They do not argue against lymphadenectomy for patients with clinical T2 and 3 tumors and clinical N1 and 2 nodes. However, for clinical N0 cancers and for postmenopausal patients with hormone-receptor-positive tumors, the authors propose radiotherapy to the axilla as a modality less expensive than surgery and with fewer complications. They suggest observation only for lesions associated with a less than 10% to 15% chance of axillary metastasis (T1a cancers, tubular carcinomas, ductal carcinoma in situ [DCIS] with microinvasion). However, for patients with lesionsless than 1 cm with “high-risk features (presence of tumor emboli in vessels, poor nuclear grade, etc),” axillary lymphadenectomy “should continue to serve as a refined prognostic indicator for selection of patients for adjuvant therapy.”